3
|
Rayasilp K, Wonganan P, Chariyavilaskul P, Prompila N, Sukkummee V, Wittayalertpanya S. Effect of Pomelo Juice on the Pharmacokinetics of Simvastatin, CYP3A2 Activity and Mdr1a, Mdr1b and Slc21a5 Expressions in Rats. PHARMACEUTICAL SCIENCES 2019. [DOI: 10.15171/ps.2019.45] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Background: Food-drug interaction can decrease drug effectiveness or increase risk of drug toxicity. Simvastatin is widely used for treatment of hypercholesterolemia and hypertriglyceridemia. Therefore, this study aimed to investigate the effects of pomelo juice on the pharmacokinetics of simvastatin, CYP3a2 activity and Mdr1a, Mdr1b and Slc21a5 expressions in rats. Methods: Rats were divided into 4 groups including (i) control, (ii) pomelo that received pomelo juice orally twice daily for 7 days, (iii) simvastatin that received simvastatin on day 8, and (iv) simvastatin + pomelo juice. Plasma concentrations of simvastatin and simvastatin acid were analyzed using LC-MS/MS. Hepatic CYP3a2 activity was evaluated using midazolam hydroxylation assay. The expressions of hepatic and intestinal Mdr1a, Mdr1b and Slc21a5 were measured using the real-time RT-PCR. Results: Oral administration of pomelo juice for 7 days altered pharmacokinetic profiles of simvastatin and its primary active metabolite, simvastatin acid, in rats. Real-time RT-PCR analysis revealed that pomelo juice significantly suppressed the expression of intestinal Mdr1a and Mdr1b and hepatic Slc21a5. Rat hepatic CYP3a2 catalytic activity was also inhibited following pomelo juice administration. Conclusion: The results of this study suggested that there was a risk of potential drug interaction associated with inhibition of drug transporters and CYP3A caused by pomelo juice.
Collapse
Affiliation(s)
- Kritsakorn Rayasilp
- Interdisciplinary Program in Pharmacology, Graduate School, Chulalongkorn University, Bangkok, Thailand
- Clinical Pharmacokinetics and Pharmacogenomics Research Unit, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Piyanuch Wonganan
- Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Pajaree Chariyavilaskul
- Clinical Pharmacokinetics and Pharmacogenomics Research Unit, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Nuntaporn Prompila
- Chula Pharmacokinetic Research Center, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Varumporn Sukkummee
- Clinical Pharmacokinetics and Pharmacogenomics Research Unit, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Supeecha Wittayalertpanya
- Clinical Pharmacokinetics and Pharmacogenomics Research Unit, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| |
Collapse
|
4
|
El-Zailik A, Cheung LK, Wang Y, Sherman V, Chow DSL. Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery. J Pharm Biomed Anal 2018; 164:258-267. [PMID: 30396053 DOI: 10.1016/j.jpba.2018.10.045] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2018] [Accepted: 10/25/2018] [Indexed: 10/28/2022]
Abstract
Statins, HMG-CoA reductase inhibitors, are considered the first line treatment of hyperlipidemia to reduce the risk of atherosclerotic cardiovascular diseases. The prevalence of hyperlipidemia and the risk of atherosclerotic cardiovascular diseases are higher in obese patients. Published methods for the quantification of statins and their active metabolites did not test for matrix effect of or validate the method in hyperlipidemic plasma. A sensitive, specific, accurate, and reliable LC-MS/MS method for the simultaneous quantification of simvastatin (SMV), active metabolite of simvastatin acid (SMV-A), atorvastatin (ATV), active metabolites of 2-hydroxy atorvastatin (2-OH-ATV), 4-hydroxy atorvastatin (4-OH-ATV), and rosuvastatin (RSV) was developed and validated in plasma with low (52-103 mg/dl, <300 mg/dl) and high (352-403 mg/dl, >300 mg/dl) levels of triglyceride. The column used in this method was ACQUITY UPLC BEH C18 column (2.1 × 100 mm I.D., 1.7 μm). A gradient elution of mobile phase A (10 mM ammonium formate and 0.04% formic acid in water) and mobile phase B (acetonitrile) was used with a flow rate of 0.4 ml/min and run time of 5 min. The transitions of m/z 436.3 → 285.2 for SMV, m/z 437.2 → 303.2 for SMV-A, m/z 559.2 → 440.3 for ATV, m/z 575.4 → 440.3 for 2-OH-ATV and 4-OH-ATV, m/z 482.3 → 258.1 for RSV, and m/z 412.3 → 224.2 for fluvastatin (internal standard, IS) were determined by Selected Reaction Monitoring (SRM) method to detect transitions ions in the positive ion mode. The assay has a linear range of 0.25 (LLOQ) -100 ng/ml for all six analytes. Accuracy (87-114%), precision (3-13%), matrix effect (92-110%), and extraction recovery (88-100%) of the assay were within the 15% acceptable limit of FDA Guidelines in variations for plasma with both low and high triglyceride levels. The method was used successfully for the quantification of SMV, ATV, RSV, and their active metabolites in human plasma samples collected for an ongoing clinical pharmacokinetic and pharmacodynamic study on patients prior to and post gastric bypass surgery (GBS).
Collapse
Affiliation(s)
- Asma El-Zailik
- Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States.
| | - Lily K Cheung
- Department of Pharmacy Practice and Clinical Health Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, United States
| | - Yang Wang
- Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States
| | - Vadim Sherman
- Department of Surgery, Houston Methodist Hospital, Houston, TX, United States
| | - Diana S-L Chow
- Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States
| |
Collapse
|
5
|
Long TJ, Cosgrove PA, Dunn RT, Stolz DB, Hamadeh H, Afshari C, McBride H, Griffith LG. Modeling Therapeutic Antibody-Small Molecule Drug-Drug Interactions Using a Three-Dimensional Perfusable Human Liver Coculture Platform. Drug Metab Dispos 2016; 44:1940-1948. [PMID: 27621203 DOI: 10.1124/dmd.116.071456] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Accepted: 09/08/2016] [Indexed: 12/16/2022] Open
Abstract
Traditional in vitro human liver cell culture models lose key hepatic functions such as metabolic activity during short-term culture. Advanced three-dimensional (3D) liver coculture platforms offer the potential for extended hepatocyte functionality and allow for the study of more complex biologic interactions, which can improve and refine human drug safety evaluations. Here, we use a perfusion flow 3D microreactor platform for the coculture of cryopreserved primary human hepatocytes and Kupffer cells to study the regulation of cytochrome P450 3A4 isoform (CYP3A4) activity by chronic interleukin 6 (IL-6)-mediated inflammation over 2 weeks. Hepatocyte cultures remained stable over 2 weeks, with consistent albumin production and basal IL-6 levels. Direct IL-6 stimulation that mimics an inflammatory state induced a dose-dependent suppression of CYP3A4 activity, an increase in C-reactive protein (CRP) secretion, and a decrease in shed soluble interleukin-6 receptor (IL-6R) levels, indicating expected hepatic IL-6 bioactivity. Tocilizumab, an anti-IL-6R monoclonal antibody used to treat rheumatoid arthritis, has been demonstrated clinically to impact small molecule drug pharmacokinetics by modulating cytochrome P450 enzyme activities, an effect not observed in traditional hepatic cultures. We have now recapitulated the clinical observation in a 3D bioreactor system. Tocilizumab was shown to desuppress CYP3A4 activity while reducing the CRP concentration after 72 hours in the continued presence of IL-6. This change in CYP3A4 activity decreased the half-life and area under the curve up to the last measurable concentration (AUClast) of the small molecule CYP3A4 substrate simvastatin hydroxy acid, measured before and after tocilizumab treatment. We conclude that next-generation in vitro liver culture platforms are well suited for these types of long-term treatment studies and show promise for improved drug safety assessment.
Collapse
Affiliation(s)
- Thomas J Long
- Comparative Biology and Safety Science Laboratory, Amgen, Inc., Cambridge, Massachusetts (T.J.L.); Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts (T.J.L., L.G.G.); Comparative Biology and Safety Science Laboratory, Amgen, Inc., Thousand Oaks, California (P.A.C., R.T.D., H.H., H.M., C.A.); Center for Gynepathology Research, Massachusetts Institute of Technology, Cambridge, Massachusetts (L.G.G.); Center for Biologic Imaging, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.); Department of Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.)
| | - Patrick A Cosgrove
- Comparative Biology and Safety Science Laboratory, Amgen, Inc., Cambridge, Massachusetts (T.J.L.); Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts (T.J.L., L.G.G.); Comparative Biology and Safety Science Laboratory, Amgen, Inc., Thousand Oaks, California (P.A.C., R.T.D., H.H., H.M., C.A.); Center for Gynepathology Research, Massachusetts Institute of Technology, Cambridge, Massachusetts (L.G.G.); Center for Biologic Imaging, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.); Department of Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.)
| | - Robert T Dunn
- Comparative Biology and Safety Science Laboratory, Amgen, Inc., Cambridge, Massachusetts (T.J.L.); Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts (T.J.L., L.G.G.); Comparative Biology and Safety Science Laboratory, Amgen, Inc., Thousand Oaks, California (P.A.C., R.T.D., H.H., H.M., C.A.); Center for Gynepathology Research, Massachusetts Institute of Technology, Cambridge, Massachusetts (L.G.G.); Center for Biologic Imaging, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.); Department of Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.)
| | - Donna B Stolz
- Comparative Biology and Safety Science Laboratory, Amgen, Inc., Cambridge, Massachusetts (T.J.L.); Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts (T.J.L., L.G.G.); Comparative Biology and Safety Science Laboratory, Amgen, Inc., Thousand Oaks, California (P.A.C., R.T.D., H.H., H.M., C.A.); Center for Gynepathology Research, Massachusetts Institute of Technology, Cambridge, Massachusetts (L.G.G.); Center for Biologic Imaging, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.); Department of Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.)
| | - Hisham Hamadeh
- Comparative Biology and Safety Science Laboratory, Amgen, Inc., Cambridge, Massachusetts (T.J.L.); Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts (T.J.L., L.G.G.); Comparative Biology and Safety Science Laboratory, Amgen, Inc., Thousand Oaks, California (P.A.C., R.T.D., H.H., H.M., C.A.); Center for Gynepathology Research, Massachusetts Institute of Technology, Cambridge, Massachusetts (L.G.G.); Center for Biologic Imaging, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.); Department of Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.)
| | - Cynthia Afshari
- Comparative Biology and Safety Science Laboratory, Amgen, Inc., Cambridge, Massachusetts (T.J.L.); Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts (T.J.L., L.G.G.); Comparative Biology and Safety Science Laboratory, Amgen, Inc., Thousand Oaks, California (P.A.C., R.T.D., H.H., H.M., C.A.); Center for Gynepathology Research, Massachusetts Institute of Technology, Cambridge, Massachusetts (L.G.G.); Center for Biologic Imaging, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.); Department of Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.)
| | - Helen McBride
- Comparative Biology and Safety Science Laboratory, Amgen, Inc., Cambridge, Massachusetts (T.J.L.); Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts (T.J.L., L.G.G.); Comparative Biology and Safety Science Laboratory, Amgen, Inc., Thousand Oaks, California (P.A.C., R.T.D., H.H., H.M., C.A.); Center for Gynepathology Research, Massachusetts Institute of Technology, Cambridge, Massachusetts (L.G.G.); Center for Biologic Imaging, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.); Department of Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.)
| | - Linda G Griffith
- Comparative Biology and Safety Science Laboratory, Amgen, Inc., Cambridge, Massachusetts (T.J.L.); Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts (T.J.L., L.G.G.); Comparative Biology and Safety Science Laboratory, Amgen, Inc., Thousand Oaks, California (P.A.C., R.T.D., H.H., H.M., C.A.); Center for Gynepathology Research, Massachusetts Institute of Technology, Cambridge, Massachusetts (L.G.G.); Center for Biologic Imaging, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.); Department of Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (D.B.S.)
| |
Collapse
|
7
|
Tao J, Jiang P, Peng C, Li M, Liu R, Zhang W. The pharmacokinetic characters of simvastatin after co-administration with Shexiang Baoxin Pill in healthy volunteers' plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1026:162-167. [PMID: 26830535 DOI: 10.1016/j.jchromb.2016.01.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2015] [Revised: 01/07/2016] [Accepted: 01/11/2016] [Indexed: 01/19/2023]
Abstract
To investigate the effect of Shexiang Baoxin Pill (SBP), a tranditional Chinese medicine, on the pharmacokinetic (PK) parameters of simvastatin in healthy volunteers' plasma, a quantitative method was developed using an Agilent G6410A rapid performance liquid chromatography (RPLC) coupled with triple quadrupole mass spectrometry system. The established method was rapid with high extraction recovery and successfully applied for the determination of simvastatin in plasma of 16 healthy volunteers. The results demonstrated that the MRT(0-∞), T1/2 and Tmax value of simvastatin were significantly decreased, while the AUC(0-t) and Cmax values of smivastatin were increased by SBP. The pharmacokinetic study demonstrated that the metabolism parameters of simvastatin could be affected by SBP and the potential drug-drug interaction should be noted in the future clinical practice.
Collapse
Affiliation(s)
- Jianfei Tao
- Pharmacy Department, Shanghai Yangsi Hosipital, Shanghai 200126, PR China
| | - Peng Jiang
- School of Pharmacy, Second Military Medical University, Shanghai 200433, PR China; Shanghai Hutchison Pharmaceuticals Company, Shanghai 200331, PR China
| | - Chengcheng Peng
- School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200030, PR China
| | - Min Li
- Department of Ophthalmology, Shanghai Tenth People's Hospital Affiliated with Tongji University, School of Medicine, Shanghai 200072, PR China
| | - Runhui Liu
- School of Pharmacy, Second Military Medical University, Shanghai 200433, PR China
| | - Weidong Zhang
- School of Pharmacy, Second Military Medical University, Shanghai 200433, PR China; School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200030, PR China.
| |
Collapse
|